CN112375073B - 抗真菌的化合物 - Google Patents

抗真菌的化合物 Download PDF

Info

Publication number
CN112375073B
CN112375073B CN202011308132.2A CN202011308132A CN112375073B CN 112375073 B CN112375073 B CN 112375073B CN 202011308132 A CN202011308132 A CN 202011308132A CN 112375073 B CN112375073 B CN 112375073B
Authority
CN
China
Prior art keywords
compound
species
spp
aqueous suspension
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011308132.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112375073A (zh
Inventor
须纳濑见广
T·C·科利
伊藤和浩
G·拉佩波特
P·斯特朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmocide Ltd
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Priority to CN202011308132.2A priority Critical patent/CN112375073B/zh
Publication of CN112375073A publication Critical patent/CN112375073A/zh
Application granted granted Critical
Publication of CN112375073B publication Critical patent/CN112375073B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/26—Power supply means, e.g. regulation thereof
    • G06F1/32—Means for saving power
    • G06F1/3203—Power management, i.e. event-based initiation of a power-saving mode
    • G06F1/3234—Power saving characterised by the action undertaken
    • G06F1/325—Power saving in peripheral device
    • G06F1/3268—Power saving in hard disk drive
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C11/00—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor
    • G11C11/21—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements
    • G11C11/34—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices
    • G11C11/40—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors
    • G11C11/401—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors forming cells needing refreshing or charge regeneration, i.e. dynamic cells
    • G11C11/4063—Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing
    • G11C11/407—Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing for memory cells of the field-effect type
    • G11C11/4074—Power supply or voltage generation circuits, e.g. bias voltage generators, substrate voltage generators, back-up power, power control circuits

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Computer Hardware Design (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202011308132.2A 2014-12-05 2015-12-04 抗真菌的化合物 Active CN112375073B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011308132.2A CN112375073B (zh) 2014-12-05 2015-12-04 抗真菌的化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14196662 2014-12-05
EP14196662.2 2014-12-05
CN201580066092.6A CN107001343B (zh) 2014-12-05 2015-12-04 抗真菌的化合物
PCT/GB2015/053731 WO2016087878A1 (en) 2014-12-05 2015-12-04 Antimycotic compound
CN202011308132.2A CN112375073B (zh) 2014-12-05 2015-12-04 抗真菌的化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580066092.6A Division CN107001343B (zh) 2014-12-05 2015-12-04 抗真菌的化合物

Publications (2)

Publication Number Publication Date
CN112375073A CN112375073A (zh) 2021-02-19
CN112375073B true CN112375073B (zh) 2024-04-16

Family

ID=52006914

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011308132.2A Active CN112375073B (zh) 2014-12-05 2015-12-04 抗真菌的化合物
CN201580066092.6A Active CN107001343B (zh) 2014-12-05 2015-12-04 抗真菌的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580066092.6A Active CN107001343B (zh) 2014-12-05 2015-12-04 抗真菌的化合物

Country Status (18)

Country Link
US (12) US10106531B2 (https=)
EP (2) EP3227277B1 (https=)
JP (2) JP6666345B2 (https=)
KR (1) KR102579848B1 (https=)
CN (2) CN112375073B (https=)
AU (1) AU2015356795B2 (https=)
BR (1) BR112017008481B1 (https=)
CA (1) CA2963625C (https=)
DK (2) DK3227278T3 (https=)
EA (1) EA033736B1 (https=)
ES (2) ES2790875T3 (https=)
HU (2) HUE048685T2 (https=)
IL (1) IL251631B (https=)
MX (1) MX370412B (https=)
PL (1) PL3227277T3 (https=)
PT (1) PT3227277T (https=)
SG (1) SG11201702835RA (https=)
WO (2) WO2016087880A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2790875T3 (es) * 2014-12-05 2020-10-29 Pulmocide Ltd Compuesto antimicótico
JP6694886B2 (ja) 2014-12-18 2020-05-20 プルモシデ リミテド ４，５−ジヒドロ−６Ｈ−チエノ［３，２−ｄ］ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス（ＲＳＶ）感染を治療するためのその使用
KR102653821B1 (ko) 2015-05-21 2024-04-02 풀모사이드 리미티드 항진균성 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-트리아졸-1-일)메틸)-5-(2,4-디플루오로페닐)테트라하이드로푸란-3-일)메톡시)-3-메틸페닐)피페라진-1-일)-n-(2-하이드록시사이클로헥실)벤즈아미드 또는 이의 약학적으로 허용가능한 염.
WO2017093491A1 (en) * 2015-12-04 2017-06-08 Pulmocide Limited Antimycotic triazole compound
RU2770033C2 (ru) * 2016-11-28 2022-04-14 Целликс Био Прайвет Лимитед Композиции и способы лечения инфекционных заболеваний ротовой полости
US11185548B2 (en) 2016-12-23 2021-11-30 Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs
EP3858357A1 (en) * 2020-01-28 2021-08-04 Diaccurate Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib
RU2770598C1 (ru) * 2021-06-29 2022-04-18 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) ПРИМЕНЕНИЕ ПРОТИВОГРИБКОВОГО СРЕДСТВА НА ОСНОВЕ 2-((4-R1-5-R2-3-(ЭТОКСИКАРБОНИЛ)ТИОФЕН-2-ИЛ)АМИНО)-4-ОКСО-4-R3-БУТ-2-ЕНОВЫХ КИСЛОТ ПО ОТНОШЕНИЮ К Candida aldicans
TW202541814A (zh) 2023-11-30 2025-11-01 瑞士商巴塞利亞阿爾斯維爾藥業國際股份有限公司 用於治療真菌感染的藥物組合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN103702993A (zh) * 2011-07-18 2014-04-02 默克专利有限公司 苯甲酰胺

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5533466A (en) * 1978-07-14 1980-03-08 Janssen Pharmaceutica Nv Novel azole derivatives and their manufacture
CH655103A5 (de) * 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU2811689A (en) 1987-11-20 1989-06-14 Schering Corporation Tri-and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039678A (en) 1989-03-23 1991-08-13 Wake Forest University Method of increasing cranial vessel proliferation by administering nimodipine
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5403937A (en) * 1993-04-30 1995-04-04 Schering Corporation Process for preparing intermediates for the synthesis of antifungal agents
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
IL112081A (en) 1993-12-21 2001-08-26 Schering Plough Corp Tetrahydrofuran derivatives, their preparation and antifungal pharmaceutical compositions containing them
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
IL118464A (en) 1995-06-02 2000-08-13 Schering Corp (2R-cis)-4-¬4-¬4-¬4¬¬-5-(2',4 dihalophenyl)-tetrahydro-5-(1-H-1,2,4,triazol-1-yl-methyl)furan-3-yl(methoxy¾phenyl¾-1-piperazinyl¬phenyl2,4,dihydro2¬(5)-1-ethyl-2-(5)hydroxy propyl¾-3H-1,2,4-triazol-3-one and pharmaceutical compositions comprising them
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
WO2002080678A1 (en) 2001-04-03 2002-10-17 Schering Corporation Antifungal composition with enhanced bioavailability
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
ES2790875T3 (es) 2014-12-05 2020-10-29 Pulmocide Ltd Compuesto antimicótico
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN103702993A (zh) * 2011-07-18 2014-04-02 默克专利有限公司 苯甲酰胺

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Environmental fungicides and triazole resistance in Aspergillus;Bowyer, Paul 等;Pest Management Science;第70卷(第02期);第173-178页 *
Mono N-arylation of piperazine(III): metal-catalyzed N-arylation and its application to the novel preparations of the antifungal posaconazole and its advanced intermediate;Hepperle, Michael 等;Tetrahedron Letters;第43卷(第18期);第3359-3363页 *
Stereoselective Grignard additions to N-formyl hydrazone: a concise synthesis of NoxafilR side chain and a synthesis of NoxafilR;Saksena, Anil K. 等;Tetrahedron Letters;第45卷(第44期);第8249-8251页 *

Also Published As

Publication number Publication date
US20210048874A1 (en) 2021-02-18
WO2016087878A1 (en) 2016-06-09
WO2016087880A1 (en) 2016-06-09
US20190023696A1 (en) 2019-01-24
BR112017008481B1 (pt) 2022-09-06
MX2017007188A (es) 2017-08-28
US20190276441A1 (en) 2019-09-12
HUE048685T2 (hu) 2020-07-28
US10487073B2 (en) 2019-11-26
CA2963625C (en) 2023-08-22
ES2786374T3 (es) 2020-10-09
HK1244795A1 (en) 2018-08-17
US20210238169A1 (en) 2021-08-05
PT3227277T (pt) 2020-04-14
US10106531B2 (en) 2018-10-23
EP3227277B1 (en) 2020-02-05
CN107001343B (zh) 2020-12-11
US10858345B2 (en) 2020-12-08
AU2015356795B2 (en) 2020-01-16
DK3227278T3 (da) 2020-04-27
HUE048905T2 (hu) 2020-08-28
US10662179B2 (en) 2020-05-26
US10093659B2 (en) 2018-10-09
EA201791174A1 (ru) 2017-10-31
CA2963625A1 (en) 2016-06-09
US20170037035A1 (en) 2017-02-09
JP6669751B2 (ja) 2020-03-18
SG11201702835RA (en) 2017-05-30
JP2017536385A (ja) 2017-12-07
PL3227277T3 (pl) 2020-08-10
JP2017536382A (ja) 2017-12-07
IL251631A0 (en) 2017-06-29
US10450304B2 (en) 2019-10-22
US10800762B2 (en) 2020-10-13
IL251631B (en) 2020-05-31
EP3227278A1 (en) 2017-10-11
EP3227277A1 (en) 2017-10-11
US11661415B2 (en) 2023-05-30
US20170320858A1 (en) 2017-11-09
JP6666345B2 (ja) 2020-03-13
MX370412B (es) 2019-12-11
US20230295133A1 (en) 2023-09-21
CN112375073A (zh) 2021-02-19
AU2015356795A1 (en) 2017-04-27
US20200031809A1 (en) 2020-01-30
DK3227277T3 (da) 2020-04-27
US12269814B2 (en) 2025-04-08
US20200239453A1 (en) 2020-07-30
KR102579848B1 (ko) 2023-09-18
US10344022B2 (en) 2019-07-09
KR20170088850A (ko) 2017-08-02
EA033736B1 (ru) 2019-11-20
US20200002320A1 (en) 2020-01-02
NZ730861A (en) 2021-04-30
US20200399253A1 (en) 2020-12-24
US11008307B2 (en) 2021-05-18
EP3227278B1 (en) 2020-02-05
BR112017008481A2 (pt) 2018-01-09
US20190023697A1 (en) 2019-01-24
CN107001343A (zh) 2017-08-01
ES2790875T3 (es) 2020-10-29

Similar Documents

Publication Publication Date Title
CN112375073B (zh) 抗真菌的化合物
US10513511B2 (en) Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof
HK40046347B (zh) 抗真菌的化合物
HK40046347A (en) Antimycotic compound
HK1244795B (en) Antimycotic compound
NZ730861B2 (en) Antimycotic compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046347

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant